채용
岗位职责:
- 作为技术转移活动的一部分,负责建立主要原材料质量标准、变更以及实施新原材料和消耗品的质量标准;
- 为复杂调查的故障排除和实验室系统的优化提供SME支持;
- 作为技术主题专家(SME),参与评估原材料和辅料的检测策略,并参与监管检查和客户稽查,以支持QC原材料活动;
- 优先考虑并专注于优化实验室系统和新技术,包括使用IT系统(例如Labware)和新仪器来实现原材料检测的现代化;
- 与QC分析开发、QC项目管理、生产、工艺科学和质量保证相关方进行跨职能合作,以实现公司目标;
- 与研究中心专家合作,领导风险评估并实施与原材料检测和质量标准相关的风险缓解策略;
- 准备并参与内部和外部审计,提供专业知识并确保所有综合方法符合全球监管标准;
- 与质量保证、生产和法规事务团队紧密合作,支持产品开发并确保无缝操作;
- 及时了解原材料测试技术的最新进展,并将相关创新融入现有流程;
- 根据ChP/USP/EP/JP指导原则支持方法开发和验证;
- 根据需要,撰写、审查并批准数据报告、超出质量标准(OOS)和趋势偏离(OOT)调查、偏差、CAPA和变更控制;
- 完成领导交办的其他任务。
任职 要求:
- 学士学位,且在GMP环境中拥有8+年经验或 拥有GMP环境工作经验6+年以上的硕士学位或 博士,具有GMP环境4+年经验;
- 5+年分析检测经验,最好有原材料检测经验;
- 具有分析检测经验,最好是在生物制药行业进行的原材料检测;
- 对原材料试验(风险评估)的基于风险的方法有深入的了解 良好的英语听说读写能力;
- 熟悉原材料检测的全球药物法规(ICH、NMPA、FDA、EMA、USP、ChP、EP);
- 卓越的沟通和领导能力,能够在跨职能团队中有效工作;
- 具有Microsoft Office、Smartsheet和实验室LIMS及ERP系统(例如SAP)的经验。
총 조회수
0
총 지원 클릭 수
0
모의 지원자 수
0
스크랩
0
비슷한 채용공고
BioNTech 소개

BioNTech
PublicBioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
1,001-5,000
직원 수
Mainz that develops immunotherapies
본사 위치
$21.7B
기업 가치
리뷰
4.0
10개 리뷰
워라밸
2.5
보상
3.8
문화
4.2
커리어
3.5
경영진
3.2
75%
친구에게 추천
장점
Innovative and cutting-edge projects
Great team and collaborative environment
Excellent benefits and flexible schedule
단점
Long working hours and high workload
Fast-paced and high-pressure environment
Management and communication issues
연봉 정보
70개 데이터
L2
L3
L4
L5
L6
Mid/L4
Intern
L2 · Data Scientist L2
0개 리포트
$53,767
총 연봉
기본급
$21,507
주식
$26,884
보너스
$5,377
$37,637
$69,897
면접 경험
1개 면접
난이도
3.0
/ 5
소요 기간
14-28주
면접 과정
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Panel Interview
5
Final Interview
6
Offer
자주 나오는 질문
Behavioral/STAR
Technical Knowledge
Past Experience
Culture Fit
Problem Solving
뉴스 & 버즈
BioNTech’s BNT323 Achieves Strong Phase 2 Response Rates in Endometrial Cancer - Oncodaily
Oncodaily
News
·
1d ago
BioNTech And Boehringer Trial Adds Dimension To Small Cell Lung Cancer Story - simplywall.st
simplywall.st
News
·
4d ago
Biontech prepares FDA application after strong phase II results in endometrial cancer - medwatch.com
medwatch.com
News
·
1w ago
BioNTech and DualityBio report positive data for trastuzumab pamirtecan - Clinical Trials Arena
Clinical Trials Arena
News
·
1w ago



